CSI Market
Sign In | Register

Neurosense Therapeutics Ltd (NRSN) Annual Cash Flow Statement

Annual · GAAP · USD millions
Access NRSN quarterly Cash Flow →
This cash flow overview for Neurosense Therapeutics Ltd spans from Dec 31 2021 to Dec 31 2025, illustrating how cash generation and usage have shifted across recent reporting periods.
View historic periods: Download as CSV:
Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.
Annual Report, GAAP in USD millions
ITEM 		(Dec 31 2025)
12 Months 		(Dec 31 2024) (Dec 31 2023) (Dec 31 2022) (Dec 31 2021)
Operating Activities
Income-11.13
Depreciation & amortization0.02
Amortization of Other Assets0.00
Extraordinary Item, Gain (Loss), Insurance Assets, Accretion Expense0.00
Restructuring & Impairment Charges0.00
Provision For Loan Losses Expensed0.00
Inventories Decrease /-Increase0.00
R & D, Environmental and Other Expense0.00
Adjustments For Gain Loss On Disposals PropertyPlant And Equipment0.00
Share-based Compensation2.14
Income (Loss) from Equity Method Investments0.00
Adjustments ForFair Value Gains Losses0.00
Adjustments For Sharebased Payments-
Finance Expense Income-
Increase In Other Receivables-
Adjustments For Increase Decrease In Trade Account Payable-
Revaluation Of Liability In Respect To Warrants-
Decrease In Operating Right Of Use Asset0.08
Decrease In Operating Lease Liability-
Income taxes3.01
Losses/ -gains on Investments net0.00
Increase (Decrease) in Accounts and Other Receivables-0.42
Accounts Payable-0.36
Accrued Expense0.00
Deferred Revenue and Customer Advances and Deposits0.00
Prepaid Expense and Other Assets0.00
Other Working Capital0.00
Other Noncash Income (Expense)0.05
Other net0.00
Payments for (Proceeds from) Other Operating Activities-0.07
Discontinued operations0.00
Net Cash flow from Operating Activities-7.67
Investing Activities
Capital Expenditures0.01
Sale of Capital Items0.00
Short-term Investments Proceeds0.00
Short-term Investments Acq.0.00
Real Estate Investments0.00
Investment In Restricted Deposits-
Redemptionofinvestment In Shortterm Deposits-
Redemption Ofinvestment In Restricted Deposit Net-
Restricted Cash and Investments Increase (Decrease)0.00
Payments for (Proceeds from) Loans0.00
Payments for (Proceeds from) Deposits0.00
Payments for (Proceeds from) Other Investments0.00
Payments for (Proceeds from) Federal Reserve and FHLB0.00
Acquisition Net of Cash Acquired0.00
Interest in Subsidiaries and Affiliates0.00
Sale of businesses0.00
Accounts payable0.00
Receivables0.00
Payments for (Proceeds from) Other Investing Activities0.00
Other Net0.00
Discontinued operations0.00
Net Cash Flow from Investing Activities-0.01
Financing Activities
Short-term debt Net0.00
Other borrowing transactions0.12
Long-term debt - borrowings0.00
Long-term debt - repayments0.00
Federal Home Loan Bank and Federal Funds0.00
Issuances / -repurchases of Comm. Stock0.01
Partnership and Parent Transactions0.00
Issuances / -repurchases of Pref. Stock4.53
Deposits, Annuities, Contract Holders Funds0.00
Other financing activities net0.00
Other net0.00
Proceeds From Issuing Shares-
Increase Decrease In Cash And Cash Equivalents-
Payments of Dividends, Preferred Stock and Preference Stock0.00
Dividends paid0.00
Net Cash Flow from Financing Activities4.43
Effect of exchange rate on cash flow0.04
Discontinued operations0.00
Free Cash Flow-7.66
Total Cash Flow0.00
4 historic quarters locked

Sign in to unlock the full Neurosense Therapeutics Ltd cash flow history.

Sign In Create Free Account

About Neurosense Therapeutics Ltd Annual Cash Flow Statement

What this statement shows

This page presents issuer-reported cash flow data, including operating, investing, financing, net, and free cash flow, as disclosed in SEC 20-F filings and normalized by CSIMarket.

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings - XBRL extraction - normalization in the CSIMarket.com database.
  • Accession: 0001213900-26-036970

Figures are derived from filed reports and may be restated. Historical data is subject to revision.

Untitled Document